We serve Chemical Name:barium cyclohexanebutyrate CAS:62669-65-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:barium cyclohexanebutyrate
CAS.NO:62669-65-2
Synonyms:Barium cyclohexanebutyrate;MFCD00036397;EINECS 263-685-7
Molecular Formula:C20H34BaO4
Molecular Weight:475.80900
HS Code:
Physical and Chemical Properties:
Melting point:225ºC (dec.)(lit.)
Boiling point:283.3ºC at 760mmHg
Density:0.991g/cm3
Index of Refraction:
PSA:52.60000
Exact Mass:476.15100
LogP:5.48900
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 1564 6.1/PG 3
Packing Group:III
Contact us for information like Barium cyclohexanebutyrate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,EINECS 263-685-7 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,EINECS 263-685-7 Use and application,Barium cyclohexanebutyrate technical grade,usp/ep/jp grade.
Related News: This further investment in enhanced facilities and continuous staff development provides the increased range of testing services required by the international biopharmaceutical industry. Ethyl 6-hydroxy-1,2-benzoxazole-3-carboxylate manufacturers Lonza is investing CHF 20 million in GMP laboratories and mid-scale manufacturing assets at its API manufacturing center in Nansha, China. The investment will allow Lonza to provide a smoother transition from small-scale to large-scale manufacturing for customers. 1,4-bis(2-ethyl-6-methylanilino)anthracene-9,10-dione suppliers “It’s truly an important scientific issue and important public health issue and FDA is actively exploring all regulatory options for providing access to additional doses of authorized vaccines in situations where data suggests the benefits would outweigh the risks,” Fink said. 2,4,6-Trichloroquinazoline vendor & factory This further investment in enhanced facilities and continuous staff development provides the increased range of testing services required by the international biopharmaceutical industry. ,Alexion has been working to push Ultomiris through additional indications ahead of Soliris’ expected loss of exclusivity in 2025.
